Canadian Agency for Drugs and Technologies in Health. (2019). CADTH Canadian drug expert committee recommendation (final): Indication : treatment of adult patients with moderate-to severe plaque psoriasis who are candidates for systemic therapy. Certolizumab pegol (Cimzia -- UCB Canada Inc.). Canadian Agency for Drugs and Technologies in Health.
Cita Chicago Style (17a ed.)Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation (final): Indication : Treatment of Adult Patients with Moderate-to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy. Certolizumab Pegol (Cimzia -- UCB Canada Inc.). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2019.
Cita MLA (9a ed.)Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation (final): Indication : Treatment of Adult Patients with Moderate-to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy. Certolizumab Pegol (Cimzia -- UCB Canada Inc.). Canadian Agency for Drugs and Technologies in Health, 2019.
